AVL Medical Instruments UK Limited

Annual Report for the year ended 31 December 2001

Registered number 2425430

A19 *AGHIFF2K* DS44

A19 **HBHIF COMPANIES HOUSE

0644 24/10/02

AVL Medical Instruments UK Limited Annual report for the year ended 31 December 2001

Directors' report for the year ended 31 December 2001

The directors present their report and the unaudited financial statements for the year ended 31 December 2001.

Principal activities

The company did not trade during the year.

Directors

The directors of the company at 31 December 2001, all of whom have been directors for the whole of the year ended on that date, are listed below:

Richard Daniel

(Great Britain)

Kaspar Fuchs

(Switzerland)

Alexander Grant

(Great Britain)

Directors' interests

No director had any interest in the shares of the company or its holding company, Roche Diagnostics Limited, during the year.

Auditors

The directors have relied upon the provisions of Sections 249AA and 388A of the Companies Act 1985 and have resolved not to appoint auditors.

By order of the board

A. Grant, Director

17th September 2002

AVL Medical Instruments UK Limited Bell Lane Lewes

East Sussex, BN7 1LG

BALANCE SHEET at 31 DECEMBER 2001

	Notes	2001 £	2000 £
CREDITORS: amounts falling due within one year		(1,556,944)	(1,556,944)
NET CURRENT (LIABILITIES)/ ASSETS		(1,556,944)	(1,556,944)
NET LIABILITIES		(1,556,944)	(1,556,944)
EQUITY CAPITAL AND RESERVES			
Called up share capital		19,304	19,304
Capital reserve		450,000	450,000
Profit and loss account		(2,026,248)	(2,026,248)
SHAREHOLDERS FUNDS		(1,556,944)	(1,556,944)

For the year ended 31 December 2001 the company was entitled to the exemption under section 249AA(1) of the Companies Act 1985.

Members have not required the company to obtain an audit in accordance with section 249(B)(2) of the Companies Act 1985.

The directors acknowledge their responsibility for:

- (i) ensuring the company keeps accounting records which comply with section 221; and
- (ii) preparing accounts which give a true and fair view of the state of affairs of the company as at the end of the financial year, and of its profit or loss for the financial year, in accordance with section 226, and which otherwise comply with the requirements of the Companies Act relating to accounts, so far as applicable to the company

The financial statements on pages 3 to 4 were approved by the board of directors on 16th September 2002 and signed on its behalf by:

A. Grant Director

The notes on page 4 form part of these accounts.

Notes to the financial statements for the year ended 31 December 2001

1 General

The company has not prepared a profit and loss account as there was no revenue during the year ended 31 December 2001; any expenses incurred by the company have been borne by the shareholders.

2 Creditors

_	Orealio13	2001 £	2000 £
	Amounts due to group undertaking	1,556,944	1,556,944
3	Called-up share capital	2001 £	2000 £
	Authorised 50,000 ordinary shares of 1 Swiss franc each	19,304	19,304
	Allotted, called-up and fully paid 50,000 ordinary shares of 1 Swiss franc each	19,304	19,304

4 Directors' emoluments

The directors received no emoluments for the year ended 31 December 2001.

5 Ultimate parent company

The company's immediate holding company is Roche Diagnostics Limited.

The company's ultimate holding company is Roche Holding AG of Switzerland.

The smallest and largest parent undertaking for which group accounts are prepared are Roche Holding (UK) Limited and Roche Holding AG of Switzerland and these accounts are obtainable from the Company Secretary, Roche Products Limited, 40 Broadwater Road, Welwyn Garden City, Hertfordshire.